Skip to main content

Table 5 Univariate and multivariate results for recurrence free survival (Discovery cohort)

From: Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer

A. Case–control approach
Parameter Univariate analysis Multivariate analysis
HR (95 % CI) p-value HR (95 % CI) p-value
Risk score 1.95 (1.16 – 3.29) 0.01 2.27 (1.33 -3.88) 0.003
Tumor stage 0.42 (0.23 – 0.76) 0.01 0.34 (0.18 – 0.65) 0.001
Tumor grade 1.52 (0.88 – 2.63) 0.14   
Age at diagnosis 1.02 (0.99 – 1.05) 0.29   
TNBC status 0.75 (0.39 – 1.41) 0.37   
B. Case-only approach Parameter
Parameter Univariate analysis Multivariate analysis
HR (95 % CI) p-value HR (95 % CI) p-value
Risk score 1.68 (0.99 – 2.82) 0.05 1.85 (1.09 – 3.14) 0.02
Tumor stage 0.42 (0.23 – 0.79) 0.01 0.38 (0.20 – 0.71) 0.003
Tumor grade 1.52 (0.88 – 2.63) 0.14   
Age at diagnosis 1.02 (0.99 – 1.05) 0.29   
TNBC status 0.75 (0.39 – 1.41) 0.37   
  1. A and B: The two and four miRNAs from Table 2A and B respectively were used to construct risk scores. Receiver Operating Characteristics Curve was used to dichotomize samples into low and high-risk groups. Univariate Cox proportional hazards regression model was run for risk score and for other clinical parameters. In the multivariate analysis, risk score was significant with p < 0.05 after adjusting for confounders.
  2. HR Hazard Ratio; CI Confidence Interval; TNBC Triple Negative Breast Cancer